Fanconi anemia (FA) is an autosomal recessive genetic syndrome characterized by progressive bone marrow failure, multiple developmental abnormalities, and an increased incidence of malignancy, especially acute myelocytic leukemia.1 A characteristic feature of the FA cell is hypersensitivity to DNA cross-linking agents, such as mitomycin C (MMC), diepoxybutane (DEB), cyclophosphamide and cisplatin.2,3 In FA cells these agents cause increased cell death, chromosome breakage, and accumulation in the G2 phase of the cell cycle.4-6 The modern diagnosis of FA depends upon finding chromosomal breakage after incubation of the patient's cells with MMC or DEB.
FA is a genetically heterogenous disorder and can be divided into at least five groups (FA-A through -E) using somatic cell hybridization and complementa tion.7,8 With analysis of a larger number of FA cell lines, at least eight complementation groups have been discovered thus far. 9 The genes defective in the FA-C and FA-A groups were identified by both expres sion10,11 and, for FA-A, positional cloning methods. Mapping of the gene defective in FA-D to chromosome 3p has been recently accomplished by using microcell mediated chromosome transfer. 12 As a stem cell disorder, FA can be effectively treated by complete replacement of patient stem cells by those from a histocompatible donor.13,14 However, allo geneic stem transplantation (BMT) is currently limited to patients with a matched sibling donor. BMT from alternative donors, while successful in selected cases, is associated with a high risk of graft failure. For FA patients lacking an appopriate donor, we have focused on the development of experimental gene therapy.
In this review we describe recent advances in our understanding of the molecular pathophysiology of FA and the development of FA-C gene therapy.
Molecular Analysis of FA
The first FA gene to be identified was the FAC gene.10 By expression cloning it was possible to isolate a cDNA that complemented the cellular defects of an FA-C cell line. The 14-exon cDNA encodes a novel protein, termed FAC, of approximately 63kD and 558 amino acids. The FAC gene has been mapped to chro mosome 9q22.3 by in situ hybridization.7 The length of the genomic DNA is greater than 100 kb.
Approximately 65% of FA patients from Europe and North America belong to complementation group A, 15-17 and the FAA cDNA has recently been identi fied by employing the same expression cloning strategy as that used to identify FAC." The FAA gene was bone marrow failure and FAC gene mutation.
NIH Experimental Trial of FAC Gene Therapy
An experimental trial of gene therapy for group C FA patients is currently ongoing at the NIH Clinical Center. This trial calls for multiple infusions of trans duced peripheral blood progenitor (PBP) cells, based on previous experimental data indicating that retro virally-marked CD34-enriched PBP cells can con tribute to long-term engraftment after autologous transplantation. For each cycle of gene transduction, patients received a 5-day course of granulocyte-colony stimulating factor subcutaneously, followed by 1-3 daily consecutive leukapheresis procedures to collect circulating hematopoietic progenitor cells. After CD34 enrichment, ex vivo transduction was performed with the G1FASvNa.52 retroviral vector (Genetic Therapy Inc.) containing the FAC gene, in the presence of stem cell factor, interleukin-6 (IL-6), and interleukin-3 (IL-3).
Three FA group C patients were entered into our clinical trial, and each patient received 3 or 4 cycles of gene transfer, each consisting of 1 or 2 infusions of the transduced autologous hematopoietic progenitor cells. Following infusion, the FAC transgene was transiently detectable by polymerase-chain reaction (PCR) in peripheral blood cells. Function of the normal FAC transgene was suggested by a marked increase in hematopoietic colonies following successive transduc tion cycles in all patients. Transient improvement in bone marrow cellularity coincided with this expansion of hematopoietic progenitors. However, despite the in vitro selective advantage resulting from FAC gene transfer, long-term hematopoietic reconstitution with gene-corrected clones was not observed. Follow-up studies showed that the number of PB mononuclear cells marked by the FAC transgene was approximately 1/1000 or fewer, as assessed by PCR methods (unpub lished data).
One major problem with gene therapy is the low efficiency of transduction to multipotent hematopoietic stem cells (HSC). If HSC do not replicate often , they may not be susceptible to retroviral transduction . Recently, cytokines have been tested for the ability to expand the growth of HSC in ex vivo culture . A study employing a new stroma-free culture system consisting of a combination of FLT3 ligand and thrombopoietin showed a dramatic expansion in hematopoietic progen itors of all lineages.30 Such protocols may enable both the expansion and replication of primitive progenitors . It may be possible to combine expansion protocols with FA gene transduction with the aim of targeting larger numbers of cycling HSC. 
